Podcasts about Lung cancer

Isaiah 53:5 says Jesus was wounded for our sin, bruised for our iniquity and with His stripes we are healed. Matthew 8:16-17 says Jesus healed all that were sick to fulfil what was spoken by the prophet Isaiah. So healing is to fulfil Bible prophecy! I talk about Bible prophecy, I write about it in Prophetic Vision magazine, but part of Bible prophecy is healing the sick. I believe Bible prophecy. Some people say that healing was only for the time of Jesus. But this prophecy is not ended. Jesus only healed for three years. There are more miracles of healing today than at any time in the history of the church – all over the world. Today in Russia this is how we are showing the glory of God, live on TV – seeing big miracles, every time I preach the Gospel! Talking of the last days in Matthew 24:14 Jesus says: ‘This Gospel shall be preached in all the world for a witness to the nations, and then shall the end come.' Jesus did not say there will be a worldwide revival. He said the preaching of the Gospel will be a witness to all nations, a demonstration to the whole world. My responsibility before God is not only to preach the Gospel, but to demonstrate the power of our God with authority. We have power in the Holy Ghost and we have authority in the Name of Jesus. I didn't go to a healing evangelist, I went to the Word of God and God completely healed me – no operation, no treatment – I only had God and the Bible, and that's all I needed to confound the doctors. They were shocked, they didn't believe God. But I do, I believe in a God of power, of miracles.

Dr Bill Nelson talks to thoracic surgeon, Dr Stephen Yang, about the developments in lung cancer surgery that have resulted in more minimally invasive procedures and improved patient outcomes.

God said to me, ‘David, you've got a mountain in your life that you've got to move, and that mountain is to get that cancer out from your lung. If you can believe that without an operation you can be completely healed, then nothing will be impossible from there on.' Now desperately seeking God's answer from Scripture, I was reading from Jeremiah 33:6, ‘I will bring health and healing'; and Jeremiah 33:20-21, ‘I will not break my covenant with David'; and Psalm 89:35, ‘I will not lie to David'; and ‘Is anything impossible with God?' (Jeremiah 32:17&27). On the Monday I was in the hospital, tubes down my lung looking for cancer – but God had already given me the answer, I knew it was gone. The doctors looked at me in amazement and said, ‘You have no cancer!' I didn't go to a healing evangelist, I went to the Word of God and God completely healed me – no operation, no treatment – I only had God and the Bible, and that's all I needed to confound the doctors. They were shocked, they didn't believe God. But I do, I believe in a God of power, of miracles.

Host Dr. Erin Gillaspie is back with a new season of the popular Best of Lung Cancer Science video podcast series. In this episode, featuring Dr. Jonathan Spicer, they break down key takeaways from the European Lung Cancer Congress, including evolving surgical approaches and how biology, AI, and real-world data are reshaping lung cancer care.

Send us Fan MailLung cancer is the leading cause of cancer deaths worldwide — but new advancements in screening, diagnosis, and treatment are changing outcomes for patients every day.In this episode of The Cass Health Podcast, pulmonologist Dr. Sumit Mukherjee joins us to talk about:Why lung cancer is often found lateWho should consider screeningWhat symptoms to watch forThe stigma around smoking & screeningThe impacts of radon exposureFuture concerns for current vaping habitsWhy he's hopeful about the future of lung cancer careWhether you're a current or former smoker, have a family history of lung cancer, or simply want to better understand your risks, this episode offers practical, understandable information.

I believe in prayer and in a God of miracles. But I am faced with a challenge: do I really believe God or not? Isaiah 53:5 says Jesus was wounded for our sin, bruised for our iniquity and with His stripes we are healed. The doctors became extremely worried, they didn't want me to travel overseas and they set up exhaustive tests in a hurry. They said bluntly, ‘It's not pneumonia, you have lung cancer.' On the following Monday I had to go for a bronchoscopy when they would put a camera down my lung and take a sample of the growth. The doctors had already fast-tracked me into a process which would lead to an operation to remove all or part of my right lung – on the Wednesday I was booked to go in for the final verdict. The only question, how much of my lung they would take away? I said, ‘Lord, how can I go back into Russia and preach like I preach and say that You are a mighty God of miracles who's got power to do everything, including healing cancer, if I have got half of my right lung cut out, followed by chemotherapy? If You have finished with me, if my ministry is over, then don't heal me, because if I can no longer evangelise I might as well die, desperately seeking God's answer from Scripture, I was reading from Jeremiah 33:6, ‘I will bring health and healing'; and Jeremiah 33:20-21, ‘I will not break my covenant with David'; and Psalm 89:35, ‘I will not lie to David'; and ‘Is anything impossible with God?' (Jeremiah 32:17&27).

In Part 2 of the ASCO 2026 Highlights series, hosts Dr. Narjust Florez and Dr. Stephen Liu are joined by Dr. Julie Brahmer and Dr. Solange Peters to discuss some of the most notable immunotherapy advances presented at the 2026 ASCO Annual Meeting. The conversation explores emerging data for PD-1/VEGF and PD-L1/VEGF bispecific antibodies, the growing role of antibody-drug conjugates in combination with immunotherapy, and promising new strategies targeting KRAS-mutant lung cancers, highlighting how these approaches may reshape the future treatment landscape. Guests: Julie R. Brahmer, MD, MSc, FASCO, FAIO The Marilyn Meyerhoff Professor of Thoracic Oncology Co-Leader, Cancer Immunology Research Program Co-Director, Upper Aerodigestive Cancers Program Director, Johns Hopkins Kimmel Cancer Center, Bayview Campus Professor Solange Peters, MD, PhD Chair of Medical Oncology Director of Oncology Department - CHUV Lausanne University Hospital

In this episode, Dr Abbie Begnaud discusses the importance of lung cancer screening and evolving strategies to improve early detection among high-risk populations, including: Low-dose CT screening, which reduces lung cancer mortality by detecting cancers at earlier, more treatable stages Updated screening guidelines that have expanded eligibility Key challenges that impact screening participation, including awareness, access, and broader risk assessment Get access to all of our new podcasts by subscribing to the Decera Clinical Education [Oncology] Podcast on Apple Podcasts, YouTube Music, or Spotify. Presenter: Abbie Begnaud, MD, FCCP Associate Professor of Medicine University of Minnesota Pulmonary, Critical Care, Allergy and Sleep Medicine Program Director, Interventional Pulmonology Fellowship University of Minnesota Health Lung Cancer Screening Program Link to full program:  Advancing the Early Detection of Lung Cancer: A Multipronged Educational Initiative to Elevate Evidence-Based Screening Practices | Decera Clinical Education Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In December 2002, as part of the process of getting a resident's permit in Ukraine, in order to prove I did not have TB which is endemic out there, I had to have a lung X-ray. But the doctors called me back, took more X-rays, and then told me I had a shadow on my lung and that I had pneumonia. Probably I had already had it for over a month, because I remember a fever had started on the last day of October while I was evangelising in Siberia. Back in England I was treated with antibiotics, but after two courses of treatment I went again for X-rays and the patch on my lung was bigger. The doctors became extremely worried, they didn't want me to travel overseas and they set up exhaustive tests in a hurry. They said bluntly, ‘It's not pneumonia, you have lung cancer.' I prayed about it, and I did go overseas to carry out my ministry, but the day after I got back the hospital process started. On the Thursday I had the CT (computer tomography) scan and it showed the cancer. I believe in prayer and in a God of miracles. But I am faced with a challenge: do I really believe God or not? Isaiah 53:5 says Jesus was wounded for our sin, bruised for our iniquity and with His stripes we are healed.

In this episode of the Oncology Brothers podcast, we discussed challenging cases focused on metastatic non-small cell lung cancer (NSCLC) with common EGFR mutations. Joined by experts Dr. Shirish Gadgeel from the Emory University and Dr. Wade Iams from Tennessee Oncology, the discussion revolved around two real-life patient cases. The first case featured a 54-year-old gentleman with active tobacco use and diffusely metastatic NSCLC, including an isolated brain lesion. The panel explored treatment options, including single-agent osimertinib versus dual combinations of amivantamab-lazertinib and osimertinib-chemotherapy, emphasizing the importance of shared decision-making and considering co-mutations and patient demographics. In the second case, the conversation shifted to supportive care and managing side effects, particularly focusing on skin toxicity associated with amivantamab. The experts shared their proactive approaches to patient education and the significance of monitoring and adjusting treatment plans to enhance patient quality of life.   Key Points: In EGFR-mutated NSCLC with CNS metastases, treatment selection between single-agent osimertinib and combination amivantamab-lazertinib vs. osimertinib-chemotherapy requires individualized consideration of age, co-mutations, extent of disease, and patient preference rather than mutation status alone. Younger patients with CNS disease may benefit from more aggressive upfront combination therapy, while shared decision-making remains central to navigating the expanded efficacy versus increased toxicity trade-off. Dermatologic toxicities associated with amivantamab requires proactive management including supportive care regimen, early dose adjustments and close patient monitoring to maintain treatment continuity. Providing the best available upfront therapy in metastatic EGFR-mutated NSCLC is critical, as sequencing options become more limited at progression. Join us for an insightful discussion on the latest treatment algorithms, the importance of personalized care, and the evolving landscape of NSCLC management.   Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966   Follow us on social media: ⁠X/Twitter: https://twitter.com/oncbrothers ⁠Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/   Don't forget to subscribe for more episodes featuring conference highlights and challenging cases in oncology! #EGFRMutated, #LungCancer, #ThoracicOncology, #PersonalizedMedicine, #OncologyBrothers

At a certain age, most women start getting regular cancer screenings: Mammograms, colonoscopies, pap smears…and yet, not for lung cancer, even though lung cancer is the most common cancer death among women in the U.S. There is currently no universal screening for lung cancer, and perhaps as a result, by the time most women are diagnosed, the prognosis is dire. For Shira Kupperman Boehler, her unexpected lung cancer diagnosis has spurred her from being a patient, to an author and policy reformer. Kupperman Boehler is founder of CANCER DOESN’T CARE, an initiative focused on advancing early lung cancer detection and prevention-focused health policy, and she is author of ONE SCAN SAVED MY LIFE: How One Woman’s Story Will Change The Way We Detect Lung Cancer.See omnystudio.com/listener for privacy information.

This episode breaks down how targeted lung cancer screening and low-dose CT scans are changing outcomes and why eligible patients should act now. Dr. David Wormuth, MD and Dr. Michael Parish, MD, thoracic surgeons at St. Joseph's Health, explain screening criteria, insurance changes, and practical next steps.

Welcome back to the Oncology Brothers podcast! In this episode, we were joined by Dr. Isabel Preeshagul from Memorial Sloan-Kettering to discuss the latest advancements in lung cancer presented at ASCO 2026. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966 Follow us on social media: X/Twitter: https://twitter.com/oncbrothers ⁠Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/ We dived into four key studies that could change clinical practice: LIBRETTO-432: exploring the promising event-free survival data with selpercatinib in RET-positive disease and its implications for adjuvant therapy. CROWN 7yr Update: seven-year progression-free survival results with lorlatinib in ALK-positive non-small cell lung cancer and the associated side effects. CHRYSALIS-2: exciting findings regarding amivantamab for atypical EGFR mutations and its potential to become the new standard of care. HARMONi-6: dual-headed drug ivonescimab combined with chemotherapy in metastatic squamous cell lung cancer and its intriguing results. We also touched on the importance of molecular testing for all patients, regardless of stage or histology, and highlighted the latest updates on tarlatamab in small cell lung cancer. Tune in for an insightful discussion that aims to keep our oncology community informed and engaged with the latest research and treatment options! Don't forget to like, subscribe, and check out our other episodes for more insights on oncology treatments, conference highlights, and FDA approvals. #ASCO2026, #LungCancer, #ALKPositive, #RETPositive, #OncologyBrothers

In this episode, Dr. Paul Wheatley-Price speaks to Dr. Ross Camidge, our guest in this increidbly unique episode of "Perspectives", sharing his leading clinical expertise on the treatment of EGFR-positive lung cancer as Director of the Thoracic Oncology at the University of Colorado Cancer Center. On the other hand, being diagnosed with the same disease himself at stage 4 in 2022, Dr. Camidge shares his perspective and journey from the patient lens, walking in the same shoes that he'd built his career upon. Don't miss this unique episode!

HOST:  Hildy Grossman CO-HOST:  Jordan Rich GUESTS: Kyle Concannon, MD, Samantha Murrell, Bianca Bye and Leah Phillips The face of lung cancer is changing. No longer viewed simply as a “smoker’s disease” that only impacts older adults, there is a rising and concerning trend of younger adults and non-smokers being diagnosed with advanced disease.  Our guests today have so much light to shine on this issue. In this powerhouse episode, we hear from Samantha Murrell, diagnosed with Stage 4 with a HER2 biomarker at age 37. She notes that her way of coping with her diagnosis was to learn everything possible about her disease. She tells how hope comes with new, cutting-edge drugs targeting HER2 because they allow her to live a full and active life.   Our guest, Leah Phillips, a mother of three young children, also was shocked by her diagnosis of Stage 4 lung cancer at 43. She tells how she joined Bianca Bye, who faced the advanced diagnosis and tragic loss of both parents, within months of each other, to lung cancer. Leah and Bianca joined forces to create the Young Lung Cancer Initiative. Oncologist, Dr. Kyle Concannon notes how these three resilient women are finding meaning in advocacy as they work to transform suffering into meaning by helping others. This is an unforgettable, action-driven look at hope, survival, and taking control.

This episode explores the rapidly evolving landscape of lung cancer treatment, from the removal of stigma in general practice to the emergence of targeted therapies, immunotherapy, and precision medicine. The panel discusses the critical role of the multidisciplinary team — particularly cancer nurses — in treatment coordination, toxicity management, and patient education, with a focus on meeting patients where they are across diverse cultural, social, and clinical backgrounds. Hosted by Melanie Rabbets, Oncology Nurse Practitioner at Blacktown Cancer Care, Western Sydney, and joined by Associate Professor Mal Itchins, Medical Oncologist and trialist at Royal North Shore Hospital and Chris O'Brien Lifehouse, Sydney, and Dr Renae Grundy, Lung Cancer Clinical Nurse Consultant at Royal Hobart Hospital, Tasmania. Sponsored by Pfizer.

Jim Brown is 58 years old and a 10+ year Stage 4 Lung Cancer Survivor from Olympia, Washington. Jim was a career firefighter and his cancer was determined to be service connected. His journey has included significant side effects from his treat including mental health and metabolic syndrome. Through fierce self advocacy and hard work he has been able to find a point of equanimity in his journey. He is still taking targeted therapy, and will for the rest of his life.   About Man Up To Cancer: Man Up To Cancer (MUTC) is a registered 501c3 nonprofit organization dedicated to inspiring men impacted by cancer to connect and avoid isolation throughout diagnosis, treatment, and survivorship. MUTC provides peer-to-peer support through 53 local chapters across the U.S. and Canada, a Chemocare Backpack Program that delivers comfort and encouragement to men in treatment, and the Gathering of Wolves, the world's largest annual retreat for men impacted by cancer. Through these programs, MUTC meets men where they are—emotionally, socially, and physically—offering community, purpose, and hope. www.manuptocancer.org ________ To learn more about the 10 Radical Remission Healing Factors, connect with a certified RR coach or join a virtual or in-person workshop visit www.radicalremission.com.   To learn more about Radical Remission health coaching with Liz or Karla, Click Here   Join our mailing list and you'll receive our free eBook, Kickstart Your Healing: 20 Radical Remission Tips, as a special thank you for joining. Subscribe Here   To watch Episode 1 of the Radical Remission Docuseries for free, visit our YouTube channel here. To purchase the full 10-episode Radical Remission Docuseries visit Hay House Online Learning. Follow us on Social Media: Facebook  Instagram YouTube ______ Our Sponsors: Connect & Thrive (CAT) is a heart-centered social impact company dedicated to supporting cancer previvors, patients, thrivers, and caregivers. CAT makes it easy for friends and family to help through intentional giving. Personalized KittyFunds™ and E-Gift Cards empower patients to begin their healing journeys by providing access to trusted integrative therapies and healthy living products not typically covered by insurance. Importantly, 100% of donations made to patients go directly to them for use in CAT's carefully curated Marketplace. By connecting patients with a supportive community and meaningful resources, CAT helps women move forward with confidence during treatment, recovery, and thrivership. CAT's mission is simple yet powerful: to help women CONNECT with a supportive community so they can truly THRIVE! “In the face of uncertainty, there is nothing wrong with hope.” ~O. Carl Simonton Visit www.connect-and-thrive.com Linkedin: https://www.linkedin.com/in/christine-anastos/ Facebook: https://www.facebook.com/CATconnectandthrive/ Instagram: https://www.instagram.com/connect_and_thrive/ _____ Nestled in the pristine, natural beauty of British Columbia, The Healing Oasis stands as Canada's first-of-its-kind cancer wellness retreat, where hope reignites and the body is empowered to heal. Here, our renowned naturopathic cancer expert, Dr. Sean Ceaser, designs a fully personalized protocol of advanced, non-toxic therapies—including high-dose IVs like mistletoe and vitamin C, cutting-edge hyperthermia, PEMF, oxygen therapy, red light, and more. Savor daily organic, cancer-fighting meals, rest deeply in serene cabins, immerse in restorative activities like forest walks and yoga, drink mineral-rich living water, and receive emotional support in a peaceful sanctuary that combines world-class care with profound nature immersion to reduce side effects, boost vitality, and spark radical healing. Your journey to feeling alive again begins today at thehealingoasis.ca. Learn More about The Healing Oasis: Website   Testimonials Video Overview

In recognition of National Women's Health Month, this episode of Thinking Thoracic analyzes the evolving landscape of female-specific lung cancer care. Co-hosts Dr. Erin Gillaspie and Dr. Jane Yanagawa sit down with guest Dr. Leah Backhus to discuss a critical disparity: lung cancer is the leading cause of cancer death among women, yet screening practices remain inequitable.    This timely episode moves beyond smoking history to examine the rise of lung cancer in never-smokers and Asian women. From the "stigma" of a diagnosis to innovative solutions like co-scheduling screenings with mammograms, providing a powerful call to action for more inclusive, biomarker-driven care. 

In this episode, pulmonologist, intensivist, and advanced bronchoscopist Huzaifah Salat joins Duane Manicini to unpack what's changing in lung cancer care, and why the biggest constraint in MedTech isn't the FDA, funding, or clinician adoption, but founders building for clinicians instead of with them. Huzaifah shares how robotic bronchoscopy, advanced imaging, and better CT quality are enabling diagnosis of tiny, moving lung nodules, and why the next wave may be non-invasive diagnostics like blood-based, saliva, or bronchial secretion testing. He offers an inside look at serving as a regional medical director and physician voice to the C-suite, where “no margin, no mission” meets patient-first priorities, and explains how diverse frontline perspectives, beyond physicians alone, shape products that truly fit real clinical workflows.Huzaifah Salat LinkedInDuane Mancini LinkedInProject Medtech WebsiteProject Medtech LinkedInThank you to our sponsors: Ward Law and JumpStart Inc.

Greek Mountain Tea is well-known in the Mediterranean region, with many traditional uses. Traditionally a tea, it can now be used as a supplement in a capsule! And don't miss the following topics that Terry will also discuss on this show: The Effects of the Keto Diet on Mental Health,  Nutrient of the Day: Quercetin,  Help for Aching Joints: Collagen,  Eating a Healthy Diet Increases Risk of Lung Cancer. Wait – WHAT?? New Study of Long COVID in Kids.

Only one in three eligible lung cancer patients receives the targeted therapy they should get.That is not a failure of science.It is a failure of delivery.After more than two decades of precision oncology, biopharma has never had better tools: cell and gene therapy, in vivo CAR-T, antibody-drug conjugates, AI-enabled diagnostics, organoids, multi-omics, and global clinical data.Yet too many breakthroughs still fail to reach the bedside.Patients fall through fragmented systems.Data does not move cleanly.Community oncologists are overloaded.Tests are missed, delayed, or misread.Promising assets die in quarterly portfolio reviews.And healthcare systems built for pills, tablets, and chronic disease management are now being asked to deliver personalized medicine at scale.In this SPARK20 highlight episode, Alasdair Milton, PhD, Principal at KPMG and leader of the firm's Precision & Advanced Therapies practice, explains why the future of biopharma will not be decided by science alone.It will be decided by translation.From lab bench to boardroom.From data to decisions.From treatment to prevention.Alasdair brings more than 20 years of experience across life sciences strategy, commercial due diligence, precision medicine, advanced therapies, cell and gene therapy, biopharma M&A, diagnostics, and global healthcare transformation.This conversation moves from the precision medicine delivery crisis to China's biotech acceleration, from AI and organoids to trapped pharma assets, from lifelong wellness to the one skill every future biotech leader needs:The ability to translate complex science into business strategy, capital allocation, and patient impact.What You'll Learn in 22 MinutesWhy only one third of eligible lung cancer patients receive targeted therapy(00:01:53)And why precision medicine still breaks in everyday clinical practice.Why science keeps compounding even when systems fail(00:04:33)Including in vivo CAR-T, functional cures, gene therapy, and antibody-drug conjugates.Why innovation does not move in a straight line(00:05:20)How technologies can look dead for years before suddenly changing the market.Why China's biotech speed matters(00:07:36)How AI, organoids, scale, and execution are changing the global innovation map.Why great science dies inside Big Pharma(00:09:20)And how deprioritized assets can become billion-dollar companies when externalized properly.Why the industry must move from sickness to lifelong wellness(00:10:03)Alasdair's vision for a more proactive, preventive, data-driven healthcare system.Why pharma needs better ways to rescue shelved assets(00:13:06)Including examples such as SpringWorks, Cerevel, and new models for unlocking trapped value.How a 400-person Scottish island shaped Alasdair's worldview(00:15:07)The personal story behind his resilience, discipline, and leadership style.Why careers and companies are never linear(00:17:19)What Alasdair learned after moving to Boston and losing his role within weeks.Why the future belongs to translators(00:20:06)The most valuable skill in biotech: explaining complex science to business leaders, investors, and boards.How to connect with Alasdair Milton and the KPMG Precision & Advanced Therapies team(00:21:47)Quotes to Carry With You

What is PD-L1, and why does it matter so much in your lung cancer treatment plan? Patient host Colette Smith talks with Dr. Julie Brahmer of Johns Hopkins University Hospital to demystify PD-L1 testing, immunotherapy decisions, and personalized lung cancer care. You'll learn: What PD-L1 is and how cancer cells use it as a "cloaking device" How Tumor Proportion Scores (TPS) from 0 to 100 guide treatment choices When immunotherapy alone works—and when chemotherapy should be added Why repeat biopsies matter for long-term survivors The most common side effects of immunotherapy and how they're managed When immunotherapy may not be the right option Key questions to ask your oncologist at every stage of treatment Why every patient should ask about clinical trials Whether you're newly diagnosed or navigating a treatment change, this conversation offers clarity, hope, and actionable guidance.  Get the full PD-L1 guide and download free patient resources: https://lcfamerica.org/about-lung-cancer/diagnosis/understand-pd-l1/ Heading to a doctor's appointment? Download LCFA's "Questions to Ask Your Care Team about PD-L1" PDF at lcfamerica.org. Learn more at lcfamerica.org. Guests: Dr. Julie Brahmer, Johns Hopkins University Hospital Colette Smith, Patient Host Show Notes - https://lcfamerica.org/wp-content/uploads/2026/05/LCFA-HWA-PD-L1-in-Lung-Cancer-Show-Notes.pdf  Transcript - https://lcfamerica.org/wp-content/uploads/2026/05/LCFA-HWA-PDL1-Transcript.pdf  YouTube - https://youtu.be/Ymff6MwaJTc  Subscribe to Hope With Answers: Living With Lung Cancer podcast for future episodes on your favorite listening platform.

In this episode, host Sylvie Legere sits down with Shira Kupperman Boehler and Dr. Kim Sandler to discuss the vital topic of early lung cancer detection. Having been diagnosed after a precautionary scan, non-smoker Shira shares her harrowing journey and advocates for change in diagnostic guidelines. Broadcasting from Wrigley Field emphasizes the importance of transforming how lung cancer is diagnosed, and how it is perceived by the medical community and public. Their conversation dives into the shortcomings of current screening guidelines and the urgent need for change to save more lives, especially for those who don't fall within the traditional risk categories. Through personal narratives and professional expertise, Dr. Sandler and Shira Kupperman Boehler share a holistic approach to detect lung cancer early by employing cutting-edge technologies and personalized medicine.  Act after listening: 1. Find out if you qualify for a free scan. If you're between 50–80 with a significant smoking history, you may be eligible for an annual low-dose CT scan — covered by Medicare and most private insurance. (Link in Resources below) 2. Ask your doctor even if you don't qualify. The current guidelines don't cover never-smokers — but that doesn't mean your risk is zero. At your next appointment, ask: "What is my personal lung cancer risk, and should I be screened?" Don't wait for symptoms. 3. Add your voice to change the guidelines. The screening criteria need to be expanded. Visit the Cancer Doesn't Care Foundation to learn how to advocate for policy change — and to share your own story if you have one. 4. Share this episode. The person who needs to hear this probably thinks they're fine. Send it to someone you love.  Guest Bios Shira Kupperman Boehler is a finance professional and health advocate with degrees in Molecular and Cell Biology from the University of California, Berkeley, and an MBA from New York University's Stern School of Business. A lifelong athlete and mother of four, she now channels her experience into raising awareness about early lung cancer detection and advancing conversations around prevention and policy. Shira and her family live in Tennessee, where she juggles life from her minivan with a coffee in one hand and a carpool schedule in the other.   Dr. Kim Lori Sandler -  Kim is a Nashville native who completed her undergraduate education at Emory University and both medical school and residency at Vanderbilt University. She trained as a cardiothoracic radiologist and is currently a Professor of Radiology and Radiological Sciences at Vanderbilt University Medical Center.  Dr. Kim is a clinician-scientist and serves as the Director of the Vanderbilt Lung Screening Program. She is a women's health advocate who is working to leverage the success of screening for breast cancer to improve enrollment of women in lung screening.  Her research also focuses on improving lung cancer risk prediction and early detection with the incorporation of machine learning and both imaging and blood-based biomarkers.  Resources & Links Visit Shira Kupperman Boehler's Website Order Shira's book ‘Cancer Doesn't Care' and learn more about Shira Boehler's campaign to change the national lung screening guidelines Take The American Lung Association's "Saved By The Scan" quiz Take the Lung Cancer Basics & Screening Eligibility Quiz from LUNGevity 

In a special edition of the This Week in Global Development podcast, Devex cofounder and Executive Vice President Alan Robbins sits down with Brazilian thoracic surgeon Dr. Ricardo Sales do Santos to discuss a revolutionary approach to tackling lung cancer in medically underserved communities in Brazil.   As the most lethal form of cancer globally, lung cancer often goes undetected until its final stages, but Dr. Santos and the Bristol Myers Squibb Foundation (are working to change that narrative through a combination of mobile technology and local capacity building. By bringing advanced CT scanning units directly into high-risk, low-income communities, they are catching tumors when they are small and potentially curable, fundamentally shifting the odds for thousands of patients.   The conversation also touches on the logistical and cultural hurdles of delivering specialized oncology care to remote areas. Dr. Santos highlights the importance of “bringing the clinic to the patient,” utilizing mobile CT units and telemedicine to bridge the gap in healthcare access. Beyond the technology, the success of the program relies heavily on empowering local health workers and community members to recognize early cancer warning signs and overcome the stigma associated with a cancer diagnosis. This approach not only improves individual health outcomes but also strengthens the broader healthcare system, offering a scalable model for global health initiatives.   To learn more about sustainable improvements in cancer care and get a compelling look at how local solutions can drive global change, listen to this special edition of This Week in Global Development. For more international development news, visit: http://www.devex.com Visit  Strengthening Care Systems — a series raising awareness of the scale of the global lung cancer burden and the systems-level changes required to address it: https://pages.devex.com/strengtheningcaresystems.html

In this episode of Lung Cancer Considered, host Dr. Narjust Florez is joined by Natalie Brown and Dr. Aurora Lucas to explore how patients and caregivers are using artificial intelligence in the context of lung cancer care. The discussion highlights real-world experiences, addressing both the benefits of AI in improving understanding and empowerment, and the risks of misinformation, overreliance, and lack of personalization. The conversation also offers practical guidance for patients, families, and clinicians on using AI responsibly while reinforcing the importance of partnership with the care team. Guests: Aurora Lucas, EdD Lung Cancer Patient Advocate Natalie S. Brown, MBA Lung Cancer Advocate & Speaker Founder, Beyond The Diagnosis LLC

Chief Medical Officer of Northwestern Medicine's Northwest region of hospitals Dr. Irfan Hafiz joins Bob Sirott to discuss what we should know about hantavirus, if electrolyte water packets have any benefits, and why doctors are finding lung cancer in younger patients. He also talks about an easy solution to alleviate allergies, an update on Ebola […]

Join Dr. Jill Valerius and host Lee Henrikson as they begin a three-part series discussing lung cancer screenings.

Lung cancer is the leading cause of cancer deaths, yet funding to support patients can be hard to come by because of the stigma attached to it. While smoking is associated with lung cancer, many people who have never smoked are diagnosed with the disease. Racquel Williams talks with Ride Hard Breathe Easy, an organization that raises funds and awareness for lung cancer patients through community bike rides, as well as a social worker at Fox Chase Cancer Center and a woman who is on her fourth battle with the disease, to understand how we can support lung cancer patients and how to get screened. Get involved or learn more about Ride Hard Breathe Easy at www.rhbe.org. Then, on Shara in the City, Shara is heading out of the city to join the circus! She gets a behind-the-scenes sneak peek at the Philly-area premiere of Cirque du Soleil's “Luzia,” at the Greater Philadelphia Expo Center in Oaks now through June 7. Tickets to “Luzia” are available at www.cirquedusoleil.com.

In this episode, Dr. Paul Wheatley-Price talks to Dr. Sara Moore about her work and experience in caring for Inuit populations in Nunavut affected by lung cancer. What is the scope of the populations she treats, the unique access barriers for diagnostics and treatment, and how their lung cancer experiences may differ than those living in Southern Canada. Dr. Moore is an Assistant Professor at University of Ottawa, Medical Oncologist and Lung Disease Site Lead at The Ottawa Hospital.

In this episode of the Oncology Brothers podcast, we dived into the world of anti-EGFR therapies in non-small cell lung cancer (NSCLC). Joined by Dr. Joshua Sabari from NYU Langone Health and Dr. Azam Farooqui from Ironwood Cancer and Research Center, we discussed the latest advancements in treatment options, including the use of osimertinib, afatinib, and the combination therapy of amivantamab and lazertinib. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966 Follow us on social media: X/Twitter: https://twitter.com/oncbrothers ⁠Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/ Key topics include: The role of afatinib in treating uncommon EGFR mutations and its associated toxicities The well-tolerated profile of osimertinib and its common side effects, including rash, diarrhea, and the rare risk of pneumonitis Insights into the combination therapy of amivantamab and lazertinib, including management of skin toxicity and the importance of prophylactic anticoagulation to mitigate VTE risks The episode emphasized the importance of maintaining quality of life for patients while ensuring they can stay on effective therapies for longer periods. Tune in for valuable clinical pearls and strategies to optimize patient care in the community setting. Don't forget to like, subscribe, and check out our other episodes for more insights on treatment algorithms and conference highlights! #LungCancer, #NSCLC, #EGFR, #TargetedTherapy, #OncologyBrothers

Welcome to the Oncology Brothers podcast! In this episode, we dived deep into the exciting world of metastatic non-small cell lung cancer (NSCLC) with a focus on targeted mutations in the frontline setting. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966 Follow us on social media: X/Twitter: https://twitter.com/oncbrothers ⁠Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/ We were joined by Dr. Eric Singhi from MD Anderson Cancer Center, to discuss the latest advancements in treatment options, including: Common EGFR mutations and the benefits of combination therapies over single-agent osimertinib. The role of CNS involvement in treatment decisions and the importance of patient-centered care. Strategies for managing disease progression and the significance of re-biopsy. Insights into ALK-positive disease, including the efficacy of lorlatinib and alectinib. The latest developments in treating rare mutations like NTRK, MET, RET, and HER2. With a wealth of clinical data and practical insights, this episode is packed with valuable information for oncologists and healthcare professionals. Tune in to learn how to navigate the complexities of NSCLC treatment and improve patient outcomes. Don't forget to subscribe for more discussions on oncology topics and share your thoughts in the comments below! #LungCancer, #TargetedTherapy, #PrecisionMedicine, #NGS, #OncologyBrothers

"Skin reactions, such as redness, dryness, and just irritation of the skin, can occur. Since we're irradiating the lung, we can also cause a cough, and that's due to the inflammation from the radiation. Patients can also get esophagitis if the tumor that we're treating is close to the midline of the chest near the esophagus. And probably the most common side effect that we see is fatigue," ONS member Amy MacRostie, RN, OCN®, radiation oncology nurse at St. Charles Cancer Center in Bend, OR, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about radiation side effects in lung cancer. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.25 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by May 8, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to the side effects of radiation to treat lung cancer. Episode Notes  Complete this evaluation for free NCPD.  ONS Podcast™ episodes: Episode 369: Lung Cancer Survivorship Considerations for Nurses Episode 363: Lung Cancer Treatment Considerations for Nurses Episode 359: Lung Cancer Screening, Early Detection, and Disparities Episode 313: Cancer Symptom Management Basics: Other Pulmonary Complications Episode 295: Cancer Symptom Management Basics: Pulmonary Embolism, Pneumonitis, and Pleural Effusion ONS Voice article: Highly Localized, Precision Radiation Therapies Require Nurses to Drive Care Coordination, Patient Education ONS book: Manual for Radiation Oncology Nursing Practice and Education (fifth edition) ONS courses: ONS/ONCC® Radiation Therapy Certificate™ ONS ROCN™ Certification Review™ ONS Radiation Learning Library ONS Guidelines™ and Symptom Intervention Resources National Comprehensive Cancer Network LUNGevity Foundation Inspire Lung Cancer Survivors Community To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "The types of radiation that can be used are external beam radiation and stereotactic body radiation treatment, or SBRT. External beam radiation is often used in combination with other treatment modalities, like chemotherapy, immunotherapy, and targeted therapy, to treat these cancers. And SBRT is usually done solo, and it's a highly precise treatment for inoperable or early-stage lung cancers." TS 1:52 "[Physicians and] providers can also help prevent side effects by reducing the dose to the heart and reducing the dose to the good lung tissue, if you will, as much as they possibly can. And this is done using intensity-modulated techniques, or IMRT. And that's where the linear accelerator sculpts the radiation beams conforming to the shape of the tumor itself." TS 6:37 "I think overall cancer treatment can lead to decreased libido and decreased sexual interest. Depression and fear can definitely play a role in this. And with lung radiation, specifically, fatigue and possibly shortness of breath with the exertion may decrease sexual interest. Nurses and providers should support the patient in their desire or lack thereof in sexual activities. We should have open discussions … and these can take place with patients about intimacy and how that can be approached in a different way that can accommodate for the side effects that the patients might be experiencing." TS 8:57 "Post-radiation scans will be abnormal. Post-radiation imaging can be misread as a progression of disease or residual disease. And I tell patients, 'Don't panic. Talk to your radiation oncologist so they can read the imaging themselves and interpret the results.' Oftentimes what's read as progression is radiation treatment sequela of scarring or fibrosis." TS 11:25

HOST: Hildy Grossman, CO-HOST: Jordan Rich GUESTS: Lecia Sequist, MD and Allison Chang, MD, Ph.D. We are building on our previous "All in the Family" episode, with Jaclyn Lo Piccolo, MD, Ph.D., Pasi Janne, MD, Ph.D., of the Dana Farber Cancer Institute and Jill Feldman from EGFR Resisters. To look deeper into how a family history of lung cancer might increase the risk for other members, we invited Drs. Lecia Sequist and Allison Chang from Mass General Hospital to discuss their latest research on risk factors and the role of family history in lung cancer. We examine the current array of diagnostic tools—from CT scans to germline genetic testing—and the mystery of why some family members are more vulnerable to environmental pollutants than others. Tune in to see how Drs. Sequist and Chang are using AI- driven CT analysis to identify risk in those with a family history of lung cancer and learn if you qualify to participate in their

What is an EGFR mutation — and could you pass it down to your children? Patient advocate Lysa Buonanno asks the questions every EGFR-positive lung cancer patient wants answered. Dr. Alice Berger, a lung cancer researcher at Fred Hutch Cancer Center, explains how EGFR mutations develop, why they are rarely inherited, and what targeted treatments — including exciting new FDA-approved options — mean for patients today. Whether you are newly diagnosed or supporting a loved one, this conversation will help you understand your biomarker results, know what to ask your doctor, and feel empowered by the science moving forward on your behalf. Topics covered: · What EGFR mutations are and how they develop · Whether EGFR mutations can be passed to children · The role of family history and genetic testing · Risk factors including radon, pollution, and smoking · Targeted therapies like osimertinib (Tagrisso) · New FDA-approved treatments for EGFR exon 20 mutations · Ongoing research into hereditary lung cancer risk Guests:  Lysa Buonanno, Patient Advocate Dr. Alice Berger, Associate Professor, Fred Hutch Cancer Center Show Notes - https://lcfamerica.org/wp-content/uploads/2026/04/LCFA-EGFR-Positive-Lung-Cancer-Show-Notes.pdf  Transcript - https://lcfamerica.org/wp-content/uploads/2026/04/LCFA-HWA-EGFR-Positive-Lung-Cancer-Transcript.pdf  Watch Video - https://youtu.be/izHAxxwZVL4  Subscribe to Hope With Answers: Living With Lung Cancer podcast for future episodes on your favorite listening platform. Join LCFA's social media communities for support and information. Facebook | Twitter | Instagram | YouTube

I've been a fan of actress and bestselling author Annabelle Gurwitch since I first read You Say Tomato, I Say Shut Up. I've interviewed her on my podcast about her last book You're Leaving When? and then got lucky enough to publish her new book, The End of My Life is Killing Me through Zibby Publishing — which has now been on the USA Today bestseller list for two weeks! You might have seen Annabelle lately because she has been all over the media with shout-outs from and interviews with Bill Maher, Drew Barrymore, Terry Gross at NPR, and Jenna Fischer. The book is hilarious and heartbreaking, fast-paced, thought-provoking, and a must-read. Hear from Annabelle and me at Totally Booked: Live in New York. ** Check out the Z.I.P. membership program—Zibby's Important People! As a Z.I.P., you'll get exclusive essays, special author access, discounts at Zibby's Bookshop, and more. Head to zibbyowens.com to subscribe or upgrade and become a Z.I.P. today!** Follow @totallybookedwithzibby on Instagram for more about today's episode. (Music by Morning Moon Music. Sound editing by TexturesSound. To inquire about advertising, please contact allie.gallo@acast.com.) Hosted on Acast. See acast.com/privacy for more information.

In this episode, Dr. Linda Chu reviews new Radiology studies exploring how photon counting CT is transforming thoracic imaging with ultra‑high resolution and dramatically lower radiation and contrast doses. She examines whether these visually striking images translate into better diagnostic confidence and meaningful improvements in patient care for emphysema and lung cancer imaging.   Ultra-Low-Dose Photon-counting Detector CT for EmphysemaAssessment: A Head-to-Head Comparative Study with Low-Dose CT. Yuan and Yang et al. Radiology 2026; 318(1):e251609.   Photon-counting CT versus Energy-integrating Detector CTin Imaging Lung Cancer. Yang et al. Radiology 2026; 318(2):e251126.   Photon-counting CT versus Energy-integrating Detector CTPerformance for Various BMI and Tumor Sizes in Lung Cancer. Zhou and Guo et al. Radiology 2026; 318(2):e251663.   Prospective Evaluation of Ultra-Low-Dose Photon-counting CT inEmphysema Assessment. Schwartz. Radiology 2026; 318(2):e254065. 

This episode of LCC covers the work of our nursing and allied health professional committee and, most importantly, highlight their role in the care of patients with thoracic malignancies. Guests: Professor Nicole Kiss is a Fellow of Dietitians Australia and Clinical Associate Professor in the Institute for Physical Activity and Nutrition at Deakin University. Nicole co-leads the Exercise and Nutrition for Cancer research group, with her research focused on early identification of cancer-related muscle loss and improving access to treatment. Dr. Morten Quist is a former IASLC Board member and is currently an Associate Professor and Research Physiotherapist at the University Hospital of Copenhagen, Rigshospitalet. For the past 25 years, he has pioneered clinical exercise-based rehabilitation for people living with cancer, with a primary focus on exercise, prehabilitation, and rehabilitation in lung cancer. His work bridges research, clinical care, patient advocacy, and voluntary engagement – always with patient wellbeing at the center.

Featuring an interview with Dr Natalie Vokes, including the following topics: Perioperative minimal residual disease (MRD) detected by circulating tumor DNA (ctDNA) testing in patients with lung cancer (0:00) Ohara S et al. Clinical significance of perioperative MRD detected by ctDNA in patients with lung cancer with a long follow-up data: An exploratory study. JTO Clin Res Rep 2024;6(3):100762. Abstract Masuda K et al. MRDSEEKER (JCOG2111A): A prospective study to evaluate MRD and its association with prognosis in curative-intent NSCLC. World Conference on Lung Cancer 2025;Abstract P3.18.04.  Zhou C et al. IMpower010: Biomarkers of disease-free survival in a phase 3 study of atezolizumab vs best supportive care after adjuvant chemotherapy in stage IB-IIIA NSCLC. ESMO IO 2021;Abstract 2O. MRD analysis of adjuvant therapy with osimertinib for resected EGFR-mutated Stage IB to IIIA non-small cell lung cancer (NSCLC) (8:28) Herbst RS et al. Molecular residual disease analysis of adjuvant osimertinib in resected EGFR-mutated stage IB-IIIA non-small-cell lung cancer. Nat Med 2025;31(6):1958-68. Abstract MRD analyses of perioperative chemoimmunotherapy for resected NSCLC (15:12) Forde PM et al. Overall survival with neoadjuvant nivolumab plus chemotherapy in lung cancer. N Engl J Med 2025;393(8):741-52. Abstract  ctDNA dynamics in advanced NSCLC treated with immunotherapy (20:56) Vokes NI et al. Circulating tumor DNA (ctDNA) dynamics and survival outcomes in patients (pts) with advanced non-small cell lung cancer (aNSCLC) and high (>50%) programmed cell death ligand 1 (PD-L1) expression, randomized to cemiplimab (cemi) vs chemotherapy (chemo). ASCO 2023;Abstract 9022. Anagnostou V et al. ctDNA response after pembrolizumab in non-small cell lung cancer: Phase 2 adaptive trial results. Nat Med 2023;29(10):2559-69. Abstract Anagnostou V et al. A biomarker-directed, multi-center phase II/III study of ctDNA molecular response adaptive immuno-chemotherapy in patients with non-small cell lung cancer (BR.36). ASCO 2025;Abstract TPS8669. CME information and select publications

Dr Natalie Vokes from The University of Texas MD Anderson Cancer Center in Houston discusses recent developments with circulating tumor DNA assays in the management of lung cancer. CME information and select publications here.

Send us Fan MailToday will be one of the most powerful episodes you will listen to in my seven-year journey as a podcaster.  We welcome Andy Speer, Head, Business Execution at Randstad Digital North America.Pain in his shoulder. A little shortness of breath. Then a monitor full of “hot spots” and a same-day referral to oncology. Andy Speer joins me on the Quarterback Dadcast and tells the story of being diagnosed with stage four lung cancer, what treatment has been like, and the one part he says is harder than everything else: telling his kids. If you've ever wondered what real resilience sounds like when the stakes are high, Andy brings it with honesty and a steady, hard-earned optimism.We also zoom out to the full Speer huddle: how Andy meets his amazing wife, Rose, young; why her “let's go where the wind takes us” mindset shapes their marriage; and what it looks like to raise four athletic, driven kids across multiple moves and life chapters. We talk practical parenting values for dads, including why trust matters more than control, why letting kids fail is part of loving them well, and why Andy's best “dad game” advice is to stop being so serious at home.On the leadership side, Andy breaks down his long career in the staffing industry, why he thrives on complexity, and what Ranstadt Digital offers customers seeking precision talent solutions. Along the way, we keep coming back to gratitude, belief, and the kind of family culture that holds up under pressure. If you care about fatherhood, family leadership, cancer mindset, and building relationships that last, this conversation will stick with you.Subscribe to the show, share this with a dad who needs it, and leave a review so more families can find these stories.Support the showPlease don't forget to leave us a review wherever you consume your podcasts!  Please help us get more dads to listen weekly and become the ultimate leader of their homes! 

Dental peeps, this one is super personal… what happens when oral care is overlooked in cancer patients? We see these patients in our ops, but what happens when that patient is your Dad? My dad... My patient In this episode of the Tooth or Dare Podcast, I share the story of my father's battle with cancer and the parts of care that too often get missed. It began with the kind of phone call no one is ever ready for: “Your dad is coughing blood.” While I'm elbow deep in a 6mm pocket during an SRP.  From that moment on, life changed quickly. Emergency visits. Hospital admissions. A diagnosis that had likely been developing quietly for some time. The truth is, many lung cancers are not found until they are already advanced. But this episode is about more than the diagnosis and the outcome being tragic. It is also about something rarely talked about enough: oral health during cancer treatment. What I learned, what we created and how I shared it with the folks at the Cancer Center. If you want the same download, you can grab it here: Oral Cancer Products Digital Download from Toothlife.ca   We discuss: ⚪ How life can change in a single moment ⚪ Warning signs that were easy to dismiss: chronic headaches, rapid weight loss, persistent coughing ⚪ The emotional reality of watching a parent go through cancer ⚪ My memories of my dad: motorcycle rides, soccer, scuba diving, and the bond we shared. #1 dental dad.  ⚪ How families can be close, yet still silent about health concerns ⚪ What hospitals commonly recommend for oral care during treatment ⚪ Why “rinse with baking soda four times a day” is not enough   Clinical + real-world insight: ⚪ A firsthand look at how oral health can be overlooked in hospital settings ⚪ The absence of dental professionals on many cancer care teams ⚪ Four separate hospital admissions within 4 months and oral hygiene was never meaningfully addressed ⚪ The effects of radiation and cancer treatment can have on the mouth ⚪ Why preventive oral care should be part of treatment planning from day one At its core, this is not a story about my loss. It is a call to do better, and perhaps for us dental people who have not seen this journey firsthand to trust me and talk about this with our patients and teams.  Oral health is connected to overall health. Always has been, not new news to us, but to the folks at the hospital, I was speaking gibberish, apparently.   And when that connection is ignored in critical care, patients feel the consequences even if they don't know it. Increased risks of infections, lower immune response... the list goes on, and we discuss that here.  A simple takeaway: Awareness → Advocacy → Integration   Because patients deserve complete care, and that includes the mouth, too.  If you made it all the way down here, hit a like and share a comment. Until next time, Peace out peeps! ✌️

We've long known that smoking can cause lung cancer. But what about air pollution? As The Allegheny Front reports, a new Appalachian study finds a connection. The post The Connection Between Pollution And Lung Cancer, This West Virginia Morning appeared first on West Virginia Public Broadcasting.

Lung cancer is one of the most common—and most misunderstood—conditions out there. The symptoms can be subtle, easy to ignore, or mistaken for something as simple as a cold.In this episode of Baptist HealthTalk, thoracic surgeon Dr. Ian Bostock breaks down what lung cancer really is, the early warning signs to watch for, and when it's time to talk to your doctor about screening.You'll learn: The difference between types of lung cancer  Why symptoms often don't appear early  Key warning signs you shouldn't ignore  Who should consider lung cancer screening  The truth about smoking, vaping, and risk  How early detection can save lives If you've ever wondered whether your symptoms are “just a cold” or something more serious, this is a must-listen.

Send us Fan MailDale Atkinson was Diagnosed with stage IV cancer, and given 11-12 months to live, this date has long since expired! HIs diagnosis was just weeks after finding out his wife had Lung Cancer. Both are very much still here, and Dale comes on the show to tell us how it all transpired, and the measures he is talking to stay alive. Dale has built his own path with evidence, food, and resilience, and he shares that journey, and how nutrition, health hacks, and the science keeps me alive! We love this episode so much! Thank you Dale, here is to you and your family!LINKS:https://www.linkedin.com/in/dalejatkinsonwww.thelifeorganic.comwww.peakhealthandfitness.co.ukSupport the show

Sign up for our newsletter! On this week's episode:   The fast pace of data center development has caught many communities off guard. Environmental organizers are trying to help them find their voices. A study released in February finds that energy generated in Pennsylvania will be used for data centers out of state. US Steel's new owner scored near the bottom in a climate ranking for steel companies. A new study tries to take smoking out of the equation for lung cancer risk. The results were surprising for areas with poor air quality. Allergy season is starting earlier because of climate change. We also talk with the author of a bird guide that's for enthusiasts and beginners alike. We're independent and non-profit, and we don't get money from WESA, WPSU or any other radio station. So we must turn to you, our listeners, for support. Take action today so we can continue to keep you informed.  Donate today.  Or send us a check to: The Allegheny Front, 67 Bedford Square, Pittsburgh, 15203.  And thanks! 

Clinical trials can feel intimidating, but they are one of the most important ways new lung cancer treatments become available to patients. In this episode of Hope With Answers: Living With Lung Cancer, patient advocate Wendy Brooks sits down with Dr. Ashish Saxena, thoracic medical oncologist at Weill Cornell Medicine, to break down what clinical trials really are and why they matter. Together, they discuss when patients should ask about clinical trials, what to expect when participating, and common misconceptions — including the fear of being a “guinea pig.” Dr. Saxena explains how clinical trials are carefully designed, closely monitored, and often provide access to promising new therapies earlier in the treatment journey. You'll learn: What clinical trials are and how they work Why timing matters and why you should ask early What patients actually receive in a clinical trial How clinical trials are improving outcomes in lung cancer What questions to ask your doctor Whether you're newly diagnosed or exploring your options, this conversation offers clear, practical insight to help you better understand clinical trials and your role in the decision-making process. Show Notes: https://lcfamerica.org/wp-content/uploads/2026/04/LCFA-HWA-Clinical-Trials-Show-Notes-2026Spring.pdf  Transcript: https://lcfamerica.org/wp-content/uploads/2026/04/LCFA-HWA-Clinical-Trials-Transcript-2026Spring.pdf  Watch Video: https://youtu.be/kBfh8EAGey8  To learn more about clinical trials and download the free toolkit, visit https://lcfamerica.org/trials.

If you've heard the term "SubQ" at your oncology appointment and weren't sure what it meant, this episode is for you. Lung cancer patient and LCFA Speakers Bureau member Stephanie Williams sits down with Dr. Coral Olazagasti, medical oncologist at the Sylvester Comprehensive Cancer Center in Miami, to break down what subcutaneous (SubQ) treatment really means — and why it's making a real difference in the daily lives of lung cancer patients. Together, they explore how SubQ injections work, how they compare to traditional IV infusions, and the quality-of-life benefits patients are experiencing: shorter clinic visits, no IV access required, less anxiety, and more time back in their day. Dr. Olazagasti also shares the exact questions patients should be asking their doctors to find out if a SubQ option is available for their treatment. Whether you're newly diagnosed or years into treatment, this conversation is a reminder that you have more options than you may realize — and that asking questions is always the right move. To learn more about SubqQ and download the free toolkit, visit https://lcfamerica.org/subq. Show Notes: https://lcfamerica.org/wp-content/uploads/2026/03/LCFA-HWA-What-Is-SubQ_-Show-Notes.pdf   Transcript: https://lcfamerica.org/wp-content/uploads/2026/03/LCFA-HWA-Subq-Treatments-Transcript.pdf   Watch Video: https://youtu.be/aQwv_ODlXs4    Subscribe to the Hope With Answers: Living With Lung Cancer podcast for future episodes on your favorite listening platform. Apple Podcasts | Spotify | Amazon Music | iHeart Join LCFA's social media communities for support and information. Facebook | Twitter/X | Instagram | YouTube

In this special sponsored episode from Eli Lilly and Company, I am joined by Dr. Lee James, senior vice president of oncology medical affairs at Lilly, to discuss the importance of lung cancer screening, early detection, and advances in biomarker testing. We explore how low-dose CT screening can reduce mortality, yet remains underused, and why comprehensive genomic profiling is essential to understanding the molecular drivers of non-small cell lung cancer and guiding targeted treatment decisions. Tune in to learn how expanding access to screening and precision medicine is helping create new hope for people affected by lung cancer. VISIT SPONSOR → https://www.lilly.com/conditions/cancer/lung-cancer SUBSCRIBE TO THE PODCAST → https://www.kevinmd.com/podcast RECOMMENDED BY KEVINMD → https://www.kevinmd.com/recommended

Kate met Shira Boehler when they were both parents at the same preschool, and the two quickly became great friends. Late last year, after a preventative screening, Shira was unexpectedly diagnosed with lung cancer, despite having no symptoms and never smoking. Early detection allowed her to undergo surgery and successfully treat the cancer. Now, Shira is determined to make lung cancer screenings accessible to everyone, especially women. She is the author of One Scan Saved My Life and the creator of the cancerdoesntcare foundation, which supports lung screening access and research. Reality Life with Kate Casey What to Watch List: https://katecasey.substack.com Patreon: http://www.patreon.com/katecasey Twitter: https://twitter.com/katecasey Instagram: http://www.instagram.com/katecaseyca Tik Tok: https://www.tiktok.com/@itskatecasey?lang=en Facebook Group: https://www.facebook.com/groups/113157919338245 Amazon List: https://www.amazon.com/shop/katecasey Like it to Know It: https://www.shopltk.com/explore/katecaseySee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.